renin-angiotensin-aldosterone system (RAAS)

Remikiren is a potent and selective inhibitor of renin, demonstrating high specificity with IC50 values of 0.7 nM for human renin and 0.8 nM for human plasma renin. This compound effectively lowers mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys, making it a valuable tool for research into hypertension. Remikiren serves as a key reagent for exploring the renin-angiotensin system and its implications in cardiovascular diseases.

Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-AMC is a specific renin substrate designed for studying renin activity. This peptide substrate facilitates the measurement of renin enzymatic activity in various biological assays, enabling researchers to investigate the renin-angiotensin system's role in cardiovascular and renal physiology. Its application includes the development of assays for screening renin inhibitors and elucidating mechanisms of blood pressure regulation.

SR 43845 is a selective renin inhibitor that effectively reduces blood pressure by inhibiting plasma renin activity. This compound is primarily used in hypertension research, providing valuable insights into the regulation of blood pressure and the renin-angiotensin system. Its application in preclinical studies can aid in the development of therapeutic strategies for hypertension management.

PD-134672 is a potent renin inhibitor featuring a 2-amino-4-thiazolyl substituent. It demonstrates significant in vitro inhibition of monkey renin, while exhibiting only minimal effects on the related protease bovine feline hepsin D. This compound has shown oral hypotensive activity in hyperreninemic normotensive monkeys and has been identified for further evaluation in renal hypertensive models due to its strong efficacy and prolonged effects. PD-134672 is a valuable tool for research exploring mechanisms of hypertension and the therapeutic potential of renin inhibition.

EMD 52297 is a potent renin inhibitor that effectively modulates hemodynamic and hormonal responses. In addition to its primary action, EMD 52297 also exhibits activity as an angiotensin-converting enzyme (ACE) inhibitor. This compound is primarily utilized in cardiovascular research and hypertension studies, providing insights into the regulation of blood pressure and renal function.

A-65317 is a primate-selective renin inhibitor that exhibits a potent inhibitory effect with an IC50 of 0.37 nM. This compound is known for its long-lasting hypotensive response, making it valuable in cardiovascular research. A-65317 can be utilized in studies focused on hypertension and renal function regulation.

Cgp 38560 methanesulfonate is a selective renin inhibitor that modulates the renin-angiotensin system. This compound exhibits a dose-dependent decrease in angiotensin II levels and plasma renin activity, while simultaneously increasing active renin concentrations. Cgp 38560 methanesulfonate is utilized in research focused on hypertension and cardiovascular disease, providing valuable insight into renin regulation and therapeutic interventions.

PD125754 is a potent oligopeptide inhibitor of renin, exhibiting an IC50 of 22 nM. This compound effectively reduces renin activity, making it valuable for studies related to hypertension and cardiovascular diseases. Its ability to modulate the renin-angiotensin system can aid in the exploration of mechanisms underlying renal and cardiovascular function.

ES-8891 is a selective renin inhibitor that effectively reduces plasma renin activity and immunoreactive renin concentrations. In a study involving normotensive sodium-depleted macaques, administration of ES-8891 led to a significant decrease in plasma angiotensin I levels and a notable reduction in mean blood pressure, without affecting heart rate. This compound serves as a valuable tool for research on blood pressure regulation and the renin-angiotensin system.

SC-46944 is an orally active renin inhibitor that effectively targets the renin-angiotensin system. It demonstrates significant potential in the study of hypertension by reducing renin activity and subsequently lowering blood pressure. This compound serves as a valuable tool in cardiovascular research and the development of antihypertensive therapies.

ES 6864 is a potent, orally active competitive inhibitor of human renin, demonstrating an IC50 of 6.9 nM and a Ki of 7.3 nM. It possesses high specificity for both species and enzyme, making it a valuable tool in cardiovascular research. Additionally, ES 6864 exhibits metabolic stability in rat tissue homogenates and effectively lowers blood pressure in rat models and sodium-depleted awake marmosets, supporting its potential applications in hypertension studies.

ACT 178882 is a potent renin inhibitor with an IC50 of 1.4 nM. It effectively modulates the renin-angiotensin-aldosterone system, leading to potential applications in the treatment of hypertension and related cardiovascular disorders. This compound serves as a valuable tool for research into the role of renin in blood pressure regulation and the development of novel antihypertensive therapies.